Kind Pharmaceuticals registers Phase 3 study of AND017 in NDD-CKD anemia
The study, led by Kind Pharmaceuticals LLC, plans to enroll 240 participants and begin in February 2027. It compares AND017 capsules with erythropoietin stimulating agents in non-dialysis-dependent chronic kidney disease patients with anemia.
Primary source
ClinicalTrials.gov registry record, November 20, 2026
A Phase III Study of AND017 to Evaluate Efficacy and Safety in NDD-CKD Associated Anemia
Read the source: A Phase III Study of AND017 to Evaluate Efficacy and Safety in NDD-CKD Associated Anemia clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation